---
schema_version: "secwatch.filing_event.v1"
accession: "0001564590-22-009633"
form_type: "8-K"
ticker: "VIVS"
cik: "0001497253"
company_name: "VivoSim Labs, INC."
filed_at: "2022-03-10T23:59:59+00:00"
generated_at: "2026-06-26T23:56:00.839693+00:00"
event_type: "leadership"
sentiment: "neutral"
materiality_score: 0.2
calibrated_materiality_score: 0.2
confidence: "high"
source: SEC EDGAR
---

# Organovo appoints Vaidehi Joshi to Board of Directors as Class I Director

## Summary
- Appointment effective March 8, 2022; term expires at 2024 annual meeting.
- Joshi brings bioprinting and drug discovery experience from Viscient Biosciences and prior Organovo role.
- Compensation: $50,000 annual retainer (pro-rated) and initial option grant of 35,000 shares at $3.47.
- Option vests quarterly over 12 quarters; accelerated on change of control.

## SEC filing metadata
- accession: 0001564590-22-009633
- form_type: 8-K
- ticker: VIVS
- cik: 0001497253
- company_name: VivoSim Labs, INC.
- filed_at: 2022-03-10T23:59:59+00:00
- event_type: leadership
- sentiment: neutral
- materiality_score: 0.2
- calibrated_materiality_score: 0.2
- confidence: high
- sec_items: 5.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1497253/000156459022009633/0001564590-22-009633-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1497253/000156459022009633/onvo-8k_20220308.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001564590-22-009633
- JSON: https://secwatch.observer/filing/0001564590-22-009633.json
- Plain text: https://secwatch.observer/filing/0001564590-22-009633.txt

## Key facts
- Executive change
  Vaidehi Joshi was appointed as Class I Director at VivoSim Labs, INC..
  - Action: appointed
  - Role: Class I Director
  source text: Effective March 8, 2022, the Board of Directors (the “Board”) of Organovo Holdings, Inc. (the “Company”) appointed Vaidehi Joshi to the Board as Class I Director.
  evidence_url: https://www.sec.gov/Archives/edgar/data/1497253/000156459022009633/0001564590-22-009633-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.